The in vitro and pharmacodynamic effects of moxifloxacin and gatifloxacin against Streptococcus pneumoniae were compared with six other fluoroquinolones. Organisms included penicillin-susceptible (54) and penicillin-non-susceptible (145) isolates from 1998-1999. Moxifloxacin and clinafloxacin demonstrated the greatest in vitro activity, with MIC 90 s of 0.13 mg/L, followed by trovafloxacin, grepafloxacin > gatifloxacin, sparfloxacin > levofloxacin > ciprofloxacin. There was no difference in fluoroquinolone activity between penicillin-susceptible and -non-susceptible strains. Pharmacodynamic analysis using published pharmacokinetic information indicates that all the agents tested except ciprofloxacin had an AUC/MIC 90 > 30, with moxifloxacin having the greatest free-drug availability.
Introduction
Streptococcus pneumoniae remains a common pathogen causing community-acquired pneumonia, sinusitis, acute exacerbations of chronic bronchitis, acute otitis media and meningitis. Multi-drug resistance has become a global threat to treatment of this organism. A surveillance study in the USA in 1999 indicated that 33% of S. pneumoniae were not fully susceptible to penicillin. 1 In the face of the increasing threat of penicillin resistance, new fluoroquinolones with enhanced Gram-positive activity have been promoted for the empirical treatment of respiratory tract infections and the specific treatment of S. pneumoniae. In vitro studies published to date have generally compared new fluoroquinolones with only a small number of agents. This study was undertaken to evaluate the in vitro activity and pharmacodynamics of two recently released fluoroquinolones, moxifloxacin and gatifloxacin, compared with ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, sparfloxacin and trovafloxacin. These antibiotics were tested against 199 clinical isolates of S. pneumoniae from a US regional surveillance study.
Materials and methods

Bacterial strains
S. pneumoniae strains (n ϭ 199) isolated during 1998-1999 were collected from clinical specimens and stored at -70ЊC.
Only one isolate per patient was included, thus excluding duplication. The isolates were collected from blood (66), respiratory secretions (132) and cerebrospinal fluid (1).
Antimicrobial agents and MICs
Antimicrobial agents as standard powders were provided by the manufacturer and included: ciprofloxacin, moxifloxacin (Bayer Corp., West Haven, CT, USA), clinafloxacin, sparfloxacin (Parke Davis, Ann Arbor, MI, USA), gatifloxacin (Bristol-Myers Squibb, Princeton, NJ, USA), grepafloxacin (Glaxo Wellcome, Research Triangle Park, NC, USA), levofloxacin (Ortho-McNeil, Puritan, NJ, USA) and trovafloxacin (Pfizer, Groton, CT, USA); the powders were used to prepare stock antibiotic dilutions as outlined in the NCCLS standards.
2 MICs were determined by broth microdilution assay, using cation adjusted Mueller-Hinton broth supplemented with 2-5% lysed horse blood (Cleveland Scientific, Bath, OH, USA). Suspensions were prepared from an 18 h pure culture in saline adjusted to a 0. 
Pharmacodynamics
Therapeutic indices were calculated by dividing published peak serum concentrations (C max ) by the appropriate MIC necessary to inhibit 90% of strains tested (MIC 90 ). AUC/ MIC 90 ratios were calculated from published pharmacokinetic data as the area under the curve (AUC) divided by the MIC 90 s determined in the study.
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Results and discussion
The susceptibility data determined for each of the antimicrobial agents tested are summarized in the Table. All fluoroquinolones tested, with the exception of ciprofloxacin and levofloxacin, had MIC 90 s Ͻ 1.0 mg/L. Ten isolates (5%) were non-susceptible to ciprofloxacin at a concentration of 4 mg/L. For these isolates there was either no or one two-fold rise in MIC 90 , which would represent an insignificant change in in vitro activity.
When evaluating quinolone activity relative to penicillin susceptibility, isolates categorized into groups as PSSP (54), PISP (78) and PRSP (67) showed no difference for any of the fluoroquinolones tested.
The in vitro activity relative to pharmacokinetics is expressed as pharmacodynamic parameters in the Table and Figure. In terms of C max /MIC 90 , these data show the rank order of activity as: moxifloxacin > clinafloxacin > gatifloxacin > trovafloxacin > grepafloxacin > levofloxacin > ciprofloxacin > sparfloxacin.
The AUC/MIC 90 ratios suggest a slightly different rank order in terms of pharmacodynamics, with: moxifloxacin > trovafloxacin > clinafloxacin > gatifloxacin > levofloxacin > grepafloxacin, sparfloxacin > ciprofloxacin. Evaluating agents in terms of free drug and total drug shows a slightly different ranking of the fluoroquinolones tested, gatifloxacin now being the second most active agent (Figure) .
When evaluating potency, the newer fluoroquinolones clearly demonstrate superior activity compared with earlier agents such as ciprofloxacin and levofloxacin. The thirdand fourth-generation fluoroquinolones both demonstrate improved potency against S. pneumoniae and anaerobes. Earlier work by Forrest et al. 6 demonstrated that ciprofloxacin achieved significantly higher microbiological and clinical cure rates when the AUC/MIC 90 exceeded 125 compared with patients with AUC/MIC 90 of Ͻ125. These data were based on the treatment of Gram-negative infections. Although these correlations are based on limited clinical experience, the observations are of interest in trying to provide better predictions of clinical response with the newer fluoroquinolones.
If we adopt an AUC/MIC 90 > 30 as necessary in selecting an effective agent, then all of the fluoroquinolones tested except for ciprofloxacin should be effective in respiratory tract infections. However, if a more conservative approach is taken as with Gram-negative organisms where the AUC/MIC 90 must exceed 100, then only trovafloxacin and moxifloxacin would meet this criterion. 7 As we are becoming more concerned with the emergence of bacterial resistance to new classes of antimicrobial agents, it seems prudent to select the most potent agent in terms of in vitro activity and potential for earliest microbiological eradication. It appears from in vitro pharmacokinetic models that agents with better pharmacodynamic activity (C max /MIC 90 > 8) may reduce the selection of resistant subpopulations. 5, 8 In addition to the in vitro activity and potency of the fluoroquinolones evaluated in this study, toxicity must be considered in the selection of any antimicrobial agent. Among the fluoroquinolones tested here, use of three agents (trovafloxacin, clinafloxacin and grepafloxacin) has either been drastically reduced in clinical practice or further development has been halted because of toxicity. Based on the clinical trials experience and the post-marketing surveillance to date, both gatifloxacin and moxifloxacin have demonstrated an acceptable safety profile. 9 In summary, whereas all the new fluoroquinolones tested in this study demonstrated enhanced in vitro activity compared with ciprofloxacin and levofloxacin, the new agent 876 Activity of new fluoroquinolones against S. pneumoniae with the greatest effect in terms of pharmacodynamics appears to be moxifloxacin.
Figure.
Comparison of the AUC/MIC ratio for fluoroquinolones tested against S. pneumoniae (, free drug; ᮀ, bound drug).
